DRKS00004918已完成不适用
Switch of anti-VEGF agents (Bevacizumab and Ranibizumab) in non-responders to anti-VEGF treatment in AMD
niversitäts-Augenklinik Freiburg0 个研究点目标入组 435 人开始时间: 2013年7月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 435
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- one 至 one（—）
- 性别
- All
入选标准
- •intravitreal injections for treatment of AMD, switch of medication after at least 3 monthly injections to the other medication after max. 100 days, at least 3 monthly injections after switch, data available for visual acuity before,a fter, and at time of switch
排除标准
- •indications other than AMD, other reasons/comorbidity for impaired visual acuity, intraocular surgery during time of study, therapy regime other than mentioned under inclusion criteria, macular hemorrhage during time of study, missing data
研究者
相似试验
招募中
不适用
Switching from existing anti-VEGF agents to ranibizumab BS in age-related macular degeneratioAge-Related Macular DegenerationJPRN-UMIN000048394agoya university75
已完成
3 期
Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial.age-relatede macular degeneration10047060NL-OMON33994Oogziekenhuis Rotterdam40
进行中（未招募）
1 期
Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial. - Anti-VEGF versus RPE-choroid graftAge related macular degeneration and either of the following conditions:1) not responding to 3 intravitreal anti-VEGF injections, or 2) pigment epithelium rip, or 3) massive haemorrhage.EUCTR2008-008259-41-NLRotterdam Eye Hospital20
进行中（未招募）
不适用
Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinomaPatients with advanced renal cell carcinomaEUCTR2006-002851-33-ATniv. Prof. Dr. Manuela Schmidinger
终止
2 期
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast CancerMetastatic Breast CancerNCT00632541Hoosier Cancer Research Network18